MedTrace Logo

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

NCT01447706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2016-05-12

Study results available
· View outcomes & findings →

Summary

To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone

Conditions

Interventions

DRUG

MM-121

MM-121 (SAR256212) (IV)

DRUG

Paclitaxel

Standard dosing Paclitaxel (IV)

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Victor Moyo, MD · Merrimack Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-09-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01447706 on ClinicalTrials.gov